Sagimet Biosciences Inc. (SGMT) company profile

The company is a clinical-stage biopharmaceutical firm that develops oral therapeutics targeting dysfunctional metabolic and fibrotic pathways. Its research focuses on fatty acid synthase inhibitors designed to treat conditions caused by excess palmitate production. Its primary drug candidate is denifanstat, an oral daily medication being evaluated for metabolic dysfunction-associated steatohepatitis, moderate to severe acne, and specific forms of cancer. Its secondary pipeline asset is TVB-3567, a small molecule candidate also aimed at treating acne. The company designs its therapies for patients suffering from liver disease, dermatological disorders, and solid tumors, and it works with commercial biopharmaceutical partners such as Ascletis to advance programs in designated territories.

The enterprise holds a proprietary library containing over 1,200 discovered compounds. Its clinical activities and collaborative clinical trials take place across the United States and Greater China, where partner-led Phase 3 trials involve hundreds of patients across multicenter sites. The provided text does not identify the location of the company's corporate headquarters.

Summary of the business section of Sagimet Biosciences's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“As of December 31, 2025, we had a total of 16 full-time employees.”